Article Figures & Data
Figures
- FIG 1.
Antithrombotic strategy management. LMWH indicates low-molecular-weight heparin; VKA, vitamin K antagonist.
- FIG 2.
Management recommendations in patients undergoing CAS with concomitant AF. Once CS (if suitable for CAS) is diagnosed, we recommend dual antiplatelet therapy (aspirin and clopidogrel) plus anticoagulation with a DOAC at least 5 days before CAS. Anticoagulation should be stopped 24 hours before CAS and re-initiated 24 hours after. According to antiplatelet therapy after CAS, we recommend a regimen including DOAC plus clopidogrel during the first month after CAS and then switching clopidogrel to aspirin.
Tables
Total (n = 91) DC Group (n = 24) TT Group(n = 42) DAPT Group (n = 25) P Age (mean) (SD) (yr) 72.27 (SD, 8.1) 72.4 (SD, 6.7) 72.6 (SD, 9) 71.6 (SD, 8.3) .9 Female sex (No.) (%) 16 (17.6) 6 (25) 8 (19) 2 (8) .119 CHAsDS2-VASc score (mean) 5.3 (SD, 1.3) 5.5 (SD, 1.1) 5.1 (SD, 1.4) 5.3 (SD, 1.4) .548 HAS-BLED score (mean) 3.9 (SD, 0.9) 3.8 (SD, 0.6) 3.8 (SD, 0.9) 4.24 (SD, 0.9) .168 Hypertension (No.) (%) 79 (86.8) 22 (91.7) 35 (83.3) 22 (88) .616 Diabetes mellitus (No.) (%) 44 (48.4) 14 (58.3) 15 (35.7) 15 (60) .082 Dyslipidemia (No.) (%) 68 (74.7) 20 (83.3) 31 (73.8) 17 (68) .459 Heart failure (No.) (%) 41 (45.1) 14 (58.3) 17 (40.5) 10 (40) .313 Smoker (No.) (%) 23 (25.27) 6 (25) 7 (16.7) 10 (40) .1 Peripheral arteriopathy (No.) (%) 18 (18.5) 3 (12.5) 6 (25) 9 (0.36) .57 Serum creatinine levels (No.) (%) <1.5 mg/dL 79 (86.8) 19 (79.2) 40 (95.2) 20 (80) .956 ≥1.5 mg/d 2 (13.2) 5 (20.8) 2 (4.8) 5 (20) DC Group TT Group DAPT Group P Major or clinically relevant nonmajor bleeding (No.) (%) 0 10 (23.8) 1 (4) .006 Major bleeding (No.) (%) 0 4 (9.5) 0 .138 Efficacy outcome Stroke (No.) (%) 0 0 1 (4) .41 Stent thrombosis (No.) (%) 1 (4.1) 0 0
